(Q80361547)
Statements
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer (English)
A H G Hansma
H J Broxterman
I van der Horst
Y Yuana
E Boven
H M Pinedo